World Library  
Flag as Inappropriate
Email this Article

Cabazitaxel

Article Id: WHEBN0027666625
Reproduction Date:

Title: Cabazitaxel  
Author: World Heritage Encyclopedia
Language: English
Subject: Chemotherapy, Cell-cycle nonspecific antineoplastic agents, Hazardous drugs, Thiopurine, Pyrimidine analogue
Collection: Acetate Esters, Benzoates, Carbamates, Microtubule Inhibitors, Mitotic Inhibitors, Taxanes
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cabazitaxel

Cabazitaxel
Systematic (IUPAC) name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-ene-2-yl benzoate
Clinical data
Trade names Jevtana
AHFS/Drugs.com
MedlinePlus
Licence data EMA:, US FDA:
Pregnancy cat.
Legal status
Routes Intravenous
Identifiers
CAS number  N
ATC code L01
PubChem
DrugBank
ChemSpider  YesY
UNII  YesY
ChEBI  N
ChEMBL  N
Chemical data
Formula C45H57NO14 
Mol. mass 835.93 g/mol
 N   

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.[1] It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.[2]

Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.

Clinical trials

In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%).[3]

References

  1. ^ http://www.cancer.gov/drugdictionary/?CdrID=534131
  2. ^ "Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review" (Press release). sanofi-aventis. 2010-06-17. Retrieved June 17, 2010. 
  3. ^ "Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere". 

External links

  • Cabazitaxel - Official web site of manufacturer.
  • Cabazitaxel Prescribing Information - Official prescribing information.
  • U.S. National Library of Medicine: Drug Information Portal - Cabazitaxel
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.